MILLERTON, OKLAHOMA – 24 Feb, 2017 – The world’s first success has been demonstrated using a new non-invasive stem-cell drug to treat diabetic sores and prevent amputation of toes and feet.
The drug, more than 96% effective, relies on a new formulation that creates stem cells deep below the skin using a highly-penetrating ointment. The drug is delivered using technology similar to that used in nicotine patches.
Diabecline is a tetracycline-based topical antibiotic developed by Phillips Company. It is FDA registered to treat cuts, scrapes and burns. It was discovered 5 years ago that, as an off-label treatment, the new drug can induce stem-cell healing; first in an animal research program followed by human research programs.
Pre-clinical evaluations and use by wound care physicians over the past 5 years have progressed to a recent clinical investigation documenting the treatment effectiveness by enrolling consecutive patients in a multi-center outpatient clinic setting.
Diabecline, when used topically, was found to be more effective than other forms of standard care, including IV antibiotics.
The healing effectiveness was greatest in those patients with the most severe wounds, including large wounds that affect deep anatomical structures below the skin. Some of these patients were last-resort patients that had failed to respond to all previous care and were headed to an amputation of toes, feet or legs. In some cases, life-threatening sores were healed with Diabecline when an amputation wasn’t feasible because of the patient’s cardiac status.
This simple topically-applied drug may be the only new drug that can save lives of older, frail patients who can not undergo surgery.
Diabecline, when used topically, was found to be more than 96% effective in healing diabetic foot ulcers. This healing effect is more pronounced in more severe sores on the feet and legs. Because of transdermal delivery of the Diabecline antibiotic, the beneficial healing effect is the same whether the wound is infected or not.
Diabetes affects almost a half a billion people globally with 23 million diabetic patients in the USA. Until recently, diabetic sores have been notoriously difficult to heal, sometimes resulting in amputation of toes and feet. Now, prevention of most diabetic amputations has become possible using a new stem-cell drug.
The treatment is the world’s first low-cost stem-cell treatment for diabetic sores. Hospitalization is not required because the non-invasive stem-cell drug can be applied topically, and there are no known side effects.
Phillips Company invites any hospital or physician to evaluate this new drug for the treatment of patients with diabetic sores, also called diabetic ulcers. The most effective on-label treatment is when the drug is used to treat minor cuts, scrapes and burns, before the condition degrades and becomes an amputation threat.
The new ointment was developed by the world’s only not-for-profit FDA-registered drug manufacturing company. For a limited time, because it is registered as an OTC drug, Diabecline is also being offered to diabetics as a research product.
Phillips Company is a pharmaceutical research company. This announcement is a research report, not an advertisement. Diabecline will be advertised after it is transferred to a larger pharmaceutical company for high-volume production.
Company Name: Phillips Company
Contact Person: Howrd Phillips, PhD
Phone: 580 746 2430
Country: United States